NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

And more pharma news updates from Pharmalittle.

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

pharmaphorum’s Managing Editor, Rebecca Aris, speaks with Gary Hendler of Eisai on Eisai’s current pipeline, what disease areas it will be focussing on and how its latest epilepsy drug ...

The decision to block Alzheimer’s ‘wonder’ drugs for use by NHS patients will be appealed against. The two breakthrough drugs ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Ivan Cheung, chairman and CEO of Eisai Inc. When speaking to people living with Alzheimer’s disease and their loved ones, the first thing I tell them is that I am sorry it has taken so long to ...

Eisai and Biogen said on Saturday the Japanese drugmaker had applied for full FDA approval of the drug. Sign up here. The drug, to be sold under the brand Leqembi, belongs to a class of treatments ...

The oncology and neurology pharmaceutical company from Japan announced rolling layoffs back in February impacting 57 employees at its headquarters in Nutley, according to a 2025 WARN notice. The ...